NewLimit
Biotechnology for extending human healthspan
CORE INFO
NewLimit is a biotechnology company that develops therapies to reverse cellular aging, focusing on improving metabolism, energy levels, and disease resilience in later life. Their initial programs target the liver, immune system, and vasculature, aiming to restore youthful function in aged cells.
- NewLimit raised $435 million in a Series C funding round in June 2026, led by Founders Fund, with participation from Thrive Capital, Greenoaks, and Quiet Capital.lw.com
- The company employs an AI-driven discovery engine to design and test thousands of epigenetic reprogramming payloads, refining their models based on experimental data to identify effective treatments.newlimit.com
WHY WE WOULD WORK AT NEWLIMIT
Transform Lives
Join a mission-driven team dedicated to extending human healthspan through innovative epigenetic reprogramming therapies that aim to reverse cellular aging.
Cutting-Edge Technology
Work with advanced technologies like functional genomics and machine learning, positioning NewLimit at the forefront of biotechnology and age-related disease treatment.
Strong Financial Backing
Benefit from substantial funding of $435 million, ensuring resources for groundbreaking research and development in healthspan extension.
Top Talent Environment
Collaborate with a diverse team of top-tier professionals, including leaders from biotech and tech industries, fostering an atmosphere of innovation and excellence.
Impactful Work
Contribute to pioneering therapies targeting critical areas like the liver and immune system, directly addressing diseases that mimic accelerated aging.
Growth Opportunities
Experience professional development in a rapidly growing company valued at $3.1 billion, with ample opportunities to advance your career in biotechnology.
MARKET AND TRACTION
TOTAL ADDRESSABLE MARKET
KEY METRICS
✦ KEY METRICGROWTH TACTICS
COMPETITIVE ADVANTAGE
MARKET POSITION
PRODUCT AND TECH
Epigenetic Reprogramming Therapies
NewLimit develops innovative therapies that aim to reverse cellular aging by reprogramming the epigenome, restoring youthful function in aged cells. These therapies target critical areas such as the liver, immune system, and vasculature to address diseases that mimic accelerated aging.
Functional Genomics
The company employs functional genomics to study the genetic factors influencing aging and cellular function. This technology is crucial for identifying potential therapeutic targets and understanding the mechanisms behind age-related diseases.
Machine Learning Models
NewLimit utilizes machine learning models to analyze complex biological data, enhancing the development of epigenetic therapies. This approach allows for more precise predictions and optimizations in the therapeutic design process.
Pooled Perturbation Screening
This methodology is used by NewLimit to systematically test the effects of various genetic modifications on cellular aging. Pooled perturbation screening helps identify key pathways and targets for therapeutic intervention.
Therapeutic Programs
NewLimit's initial therapeutic programs focus on critical health areas, including liver health and immune function, aiming to develop treatments that can significantly enhance healthspan and combat age-related diseases.